Latest Period
Q4 2025
Security Snapshot
Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) Institutional Ownership
CUSIP: 03237H101
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
180
Shares (Excl. Options)
112,323,151
Price
$12.08
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- AMLX on Nasdaq
- Shares outstanding
- 109,540,561
- Price per share
- $16.47
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 112,323,151
- Total reported value
- $1,356,917,347
- % of total 13F portfolios
- 0.01%
- Share change
- +2,426,275
- Value change
- +$21,178,257
- Number of holders
- 180
- Price from insider filings
- $16.47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 03237H101.
- 180 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 180 to 29 between Q4 2025 and Q1 2026.
- Reported value moved from $1,356,917,347 to $10,727,438.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 180 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03237H101?
CUSIP 03237H101 identifies AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03237H101:
Significant Owners of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +39% | $198,938,502 | +$61,477,681 | 16,468,419 | +45% | FMR LLC | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC | 8.2% | -6.7% | $121,662,640 | +$14,650,251 | 8,952,365 | +14% | Perceptive Advisors LLC | 30 Sep 2025 |
| BlackRock, Inc. | 7.1% | +32% | $94,027,246 | +$34,623,342 | 7,783,648 | +58% | BlackRock, Inc. | 31 Dec 2025 |
| TCG Crossover GP II, LLC | 5.7% | $74,863,306 | 6,243,812 | TCG Crossover GP II, LLC | 31 Dec 2025 | |||
| Commodore Capital LP | 5.1% | $89,213,500 | 5,650,000 | Commodore Capital LP | 10 Nov 2025 | |||
| Point72 Asset Management, L.P. | 2.6% | -54% | $38,074,233 | -$26,039,432 | 2,801,636 | -41% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 2.5% | -64% | $33,296,889 | -$48,436,878 | 2,777,055 | -59% | Adage Capital Management, L.P. | 31 Dec 2025 |
| Panacea Innovation Ltd | 2.6% | $11,792,000 | 2,200,000 | Panacea Venture Healthcare Fund II, L.P. | 31 Dec 2024 |
As of 31 Dec 2025, 180 institutional investors reported holding 112,323,151 shares of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX). This represents 103% of the company’s total 109,540,561 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 16,518,419 | +45% | 0.01% | $199,542,502 |
| BlackRock, Inc. | 8.3% | 9,054,431 | +27% | 0% | $109,377,525 |
| PERCEPTIVE ADVISORS LLC | 7.6% | 8,284,882 | -7.5% | 1.8% | $100,081,375 |
| TCG Crossover Management, LLC | 5.7% | 6,243,812 | 0% | 2.5% | $75,425,249 |
| VANGUARD GROUP INC | 5.3% | 5,804,912 | +10% | 0% | $70,123,336 |
| Commodore Capital LP | 5.2% | 5,650,000 | +39% | 4.5% | $68,252,000 |
| Saturn V Capital Management LP | 4.1% | 4,496,487 | -2.4% | 10% | $54,317,563 |
| JANUS HENDERSON GROUP PLC | 4.1% | 4,465,872 | +76% | 0.02% | $53,992,392 |
| First Light Asset Management, LLC | 3.1% | 3,355,539 | -0.01% | 3.1% | $40,534,911 |
| Driehaus Capital Management LLC | 2.8% | 3,109,503 | +28% | 0.26% | $37,562,796 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.5% | 2,777,055 | -59% | 0.05% | $33,546,824 |
| GOLDMAN SACHS GROUP INC | 2.4% | 2,613,221 | +30% | 0% | $31,567,709 |
| MORGAN STANLEY | 2.2% | 2,359,824 | +21% | 0% | $28,506,673 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,165,534 | +20% | 0% | $26,163,536 |
| Almitas Capital LLC | 1.9% | 2,122,597 | 0% | 5.6% | $25,640,972 |
| STATE STREET CORP | 1.9% | 2,069,884 | +28% | 0% | $25,004,199 |
| GREAT POINT PARTNERS LLC | 1.6% | 1,750,000 | +2.9% | 6.9% | $21,140,000 |
| 683 Capital Management, LLC | 1.5% | 1,650,000 | -6.2% | 1.7% | $19,932,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.4% | 1,513,148 | +0.04% | 0.29% | $18,278,773 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,336,010 | +211% | 0% | $16,139,001 |
| DEUTSCHE BANK AG\ | 1.2% | 1,333,236 | -2.4% | 0.01% | $16,105,491 |
| FRANKLIN RESOURCES INC | 1.1% | 1,200,096 | 0% | $14,497,160 | |
| Connor, Clark & Lunn Investment Management Ltd. | 0.92% | 1,004,021 | -9.3% | 0.03% | $12,128,574 |
| Logos Global Management LP | 0.87% | 950,000 | -34% | 0.76% | $11,476,000 |
| NORTHERN TRUST CORP | 0.86% | 937,764 | +14% | 0% | $11,328,189 |
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 771,527 | $10,727,438 | +$3,213,220 | $13.90 | 29 |
| 2025 Q4 | 112,323,151 | $1,356,917,347 | +$21,178,257 | $12.08 | 180 |
| 2025 Q3 | 109,720,694 | $1,491,122,082 | +$396,029,872 | $13.59 | 168 |
| 2025 Q2 | 81,690,006 | $523,632,250 | +$57,316,535 | $6.41 | 131 |
| 2025 Q1 | 73,877,500 | $261,528,744 | +$85,099,354 | $3.54 | 134 |
| 2024 Q4 | 49,784,011 | $188,180,501 | +$19,458,443 | $3.78 | 120 |
| 2024 Q3 | 43,406,257 | $140,608,833 | +$5,128,506 | $3.24 | 107 |
| 2024 Q2 | 43,632,024 | $82,904,189 | -$16,885,307 | $1.90 | 115 |
| 2024 Q1 | 49,485,594 | $140,539,742 | -$234,955,037 | $2.84 | 138 |
| 2023 Q4 | 60,281,638 | $887,348,868 | -$11,902,243 | $14.72 | 177 |
| 2023 Q3 | 58,927,724 | $1,078,966,869 | +$84,065,478 | $18.31 | 168 |
| 2023 Q2 | 54,545,075 | $1,176,653,052 | +$56,163,167 | $21.57 | 153 |
| 2023 Q1 | 51,372,917 | $1,507,231,117 | +$73,671,274 | $29.34 | 145 |
| 2022 Q4 | 48,572,530 | $1,794,757,212 | +$422,522,242 | $36.95 | 131 |
| 2022 Q3 | 36,858,311 | $1,037,561,470 | +$315,174,073 | $28.15 | 90 |
| 2022 Q2 | 26,621,859 | $512,910,346 | +$65,322,870 | $19.26 | 74 |
| 2022 Q1 | 23,420,880 | $299,935,403 | +$299,912,422 | $12.85 | 72 |